Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis

(2013) M. Wolfl et al.   BLOOD

Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40

(2012) Y. Yang et al.   BLOOD

Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells

(2012) M. Z. Noman et al.   CANCER RESEARCH

Myeloid-derived Suppressor Cells Adhere to Physiologic STAT3- vs STAT5-dependent Hematopoietic Programming, Establishing Diverse Tumor-Mediated Mechanisms of Immunologic Escape

(2012) Peter A. Cohen et al.   IMMUNOLOGICAL INVESTIGATIONS

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

(2012) S Mustjoki et al.   LEUKEMIA

Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model

(2012) Anamika Bose et al.   MELANOMA RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

(2011) Massimo Breccia et al.   BIODRUGS

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

(2011) A P Algazi et al.   BRITISH JOURNAL OF CANCER

Antiangiogenic Agent Sunitinib Transiently Increases Tumor Oxygenation and Suppresses Cycling Hypoxia

(2011) S. Matsumoto et al.   CANCER RESEARCH

Blocking Hypoxia-Induced Autophagy in Tumors Restores Cytotoxic T-Cell Activity and Promotes Regression

(2011) M. Z. Noman et al.   CANCER RESEARCH

PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment

(2011) N. Obermajer et al.   CANCER RESEARCH

Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors

(2011) J. C. Montero et al.   CLINICAL CANCER RESEARCH

Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma

(2011) Nagendra Natarajan et al.   DRUGS

Hypoxia-Dependent Inhibition of Tumor Cell Susceptibility to CTL-Mediated Lysis Involves NANOG Induction in Target Cells

(2011) Meriem Hasmim et al.   JOURNAL OF IMMUNOLOGY

Current Status of Src Inhibitors in Solid Tumor Malignancies

(2011) L. N. Puls et al.   ONCOLOGIST

A Case of Acute Colitis with Severe Rectal Bleeding in a Patient with Chronic Myeloid Leukemia after Dasatinib Use

(2010) Murat Erkut et al.   ACTA HAEMATOLOGICA

A phase 2 trial of dasatinib in advanced melanoma

(2010) Harriet M. Kluger et al.   CANCER

Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects

(2010) M. Kujawski et al.   CANCER RESEARCH

Targeting immune suppressing myeloid-derived suppressor cells in oncology

(2010) Johnny Kao et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

(2010) Peter Rohon et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Dasatinib in solid tumors

(2010) Lori C Kim et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

(2010) Anamika Bose et al.   INTERNATIONAL JOURNAL OF CANCER

Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

(2010) Sara M Tinsley   JOURNAL OF CLINICAL NURSING

Lck is a key target of imatinib and dasatinib in T-cell activation

(2010) K C Lee et al.   LEUKEMIA

Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery

(2010) T. D. Tailor et al.   MOLECULAR CANCER THERAPEUTICS

Intratumoral IL-12 Gene Therapy Results in the Crosspriming of Tc1 Cells Reactive Against Tumor-associated Stromal Antigens

(2010) Xi Zhao et al.   MOLECULAR THERAPY

Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling

(2009) N. Qayum et al.   CANCER RESEARCH

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

(2009) H. Xin et al.   CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

The Cooperative Induction of Hypoxia-Inducible Factor-1  and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis

(2009) M. Z. Noman et al.   JOURNAL OF IMMUNOLOGY

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

(2009) S Mustjoki et al.   LEUKEMIA

SEVERE HEMORRHAGIC COLITIS CAUSED BY DASATINIB IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

(2009) Tomoyuki Shimokaze et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Validation of PDGFR  and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

(2008) A. M. L. Coluccia et al.   BLOOD

Dasatinib inhibits the proliferation and function of CD4+CD25+regulatory T cells

(2008) Fei Fei et al.   BRITISH JOURNAL OF HAEMATOLOGY

Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib

(2008) R. Weichsel et al.   CLINICAL CANCER RESEARCH

Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia

(2008) M. V. Sitkovsky et al.   CLINICAL CANCER RESEARCH

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

(2008) Sergio A. Quezada et al.   JOURNAL OF EXPERIMENTAL MEDICINE